AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2018
Mar 28, 2018
34891_dirs_2018-03-27_58583621-56c4-4f9a-83b8-025934788502.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27
Reporting Person: Thistle Mary (Director)
More from Q32 Bio Inc.
Capital/Financing Update
2026
May 27
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Capital/Financing Update
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27